Pancreatic Cancer Drugs Global Market Report 2024
March 07, 2024 04:09 ET
|
Research and Markets
Dublin, March 07, 2024 (GLOBE NEWSWIRE) -- The "Pancreatic Cancer Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The pancreatic cancer drugs market size...
$3.4+ Billion Worldwide Pancreatic Cancer Drugs Industry to 2031 - Identify Growth Segments for Investment
April 14, 2022 06:38 ET
|
Research and Markets
Dublin, April 14, 2022 (GLOBE NEWSWIRE) -- The "Pancreatic Cancer Drugs Global Market Report 2022, Type, End User, Drugs" report has been added to ResearchAndMarkets.com's offering. This report...
World Pancreatic Cancer Clinical Landscape Spotlight 2021-2031
June 11, 2021 05:33 ET
|
Research and Markets
Dublin, June 11, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Pancreatic Cancer" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers the Pancreatic...
Global Pancreatic Cancer Opportunity Analysis and Forecasts Report 2020: Market Expected to Grow at 11.5% CAGR to $5.4B During 2019-2029
January 06, 2021 11:03 ET
|
Research and Markets
Dublin, Jan. 06, 2021 (GLOBE NEWSWIRE) -- The "Pancreatic Cancer - Opportunity Analysis and Forecasts to 2029" report has been added to ResearchAndMarkets.com's offering. Pancreatic cancer is...
Mateon Therapeutics Selects IQVIA for its Randomized, Controlled, Multi-Center Clinical Study to Test OT-101 as a Treatment for COVID-19 Patients
June 23, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, has selected IQVIA to manage C001, a Phase 2 randomized,...
PharmaCyte Biotech Addressing Unmet Need in Patients with LAPC as Pancreatic Cancer 5-Year Survival Rate Increases to 10%
January 14, 2020 09:00 ET
|
PharmaCyte Biotech
NEW YORK, NY, Jan. 14, 2020 (GLOBE NEWSWIRE) -- This month the American Cancer Society announced that for the first time ever, the 5-year survival rate for pancreatic cancer has reached double...
BeiGene Announces Acceptance of Supplemental Import Drug Application in China for ABRAXANE® in Metastatic Pancreatic Cancer
May 30, 2019 19:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, May 30, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
World-Renowned Oncologist Bullish on Potential of PharmaCyte’s Technology, Clinical Trial in Pancreatic Cancer
January 23, 2019 09:25 ET
|
PharmaCyte Biotech
NEW YORK, NY, Jan. 23, 2019 (GLOBE NEWSWIRE) -- With PharmaCyte Biotech, Inc.’s (OTCQB: PMCB) naming of Medpace, Inc., a global full-service clinical contract research organization (CRO) to conduct...
PharmaCyte Closing in on Submission of Crucial Investigational New Drug Application to Begin Clinical Trial in Pancreatic Cancer
May 21, 2018 09:20 ET
|
PharmaCyte Biotech
NEW YORK, NY, May 21, 2018 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has reached the proverbial “home stretch” regarding its efforts to submit an Investigational New Drug Application...
PharmaCyte Biotech Moves Closer to Enrolling Patients in Pancreatic Cancer Clinical Trial
December 01, 2016 09:00 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - December 01, 2016) - PharmaCyte Biotech (OTCQB: PMCB) is now one step closer to enrolling patients in a pivotal clinic trial in advanced, inoperable pancreatic cancer...